ACHV's Losses Widen Amid Soaring R&D, Admin Costs

TL;DR

**ACHV is burning cash at an alarming rate, making its future dependent on successful clinical trials and further dilutive financing.**

AI Summary

Achieve Life Sciences, Inc. (ACHV) reported a significant increase in net loss and operating expenses for the nine months ended September 30, 2025, compared to the same period in 2024. The net loss widened to $39.986 million in 2025 from $27.467 million in 2024, representing a 45.6% increase. This was primarily driven by a substantial rise in total operating expenses, which grew to $40.149 million in 2025 from $26.879 million in 2024, an increase of 49.4%. Research and development expenses increased to $19.124 million from $15.521 million, while general and administrative expenses surged to $21.025 million from $11.358 million. Despite these losses, the company's cash, cash equivalents, and marketable securities increased to $48.114 million as of September 30, 2025, from $34.360 million at December 31, 2024, largely due to successful financing activities, including a June 2025 public offering that generated $41.140 million and an additional $4.004 million from an overallotment option. The company continues to operate with a substantial accumulated deficit of $245.564 million as of September 30, 2025, and faces going concern uncertainty, relying on future financing to fund its cytisinicline development.

Why It Matters

Achieve Life Sciences' widening losses and reliance on future financing are critical for investors, signaling continued cash burn in pursuit of cytisinicline's approval. The substantial increase in R&D and G&A expenses reflects intensified efforts but also heightens financial risk. For employees, the going concern uncertainty could impact job security, while customers await a potential new treatment for nicotine dependence. In the competitive landscape of smoking cessation, successful FDA approval of cytisinicline is paramount for ACHV to carve out market share against established therapies and emerging alternatives.

Risk Assessment

Risk Level: high — The company explicitly states "Substantial doubt exists as to our ability to continue as a going concern" and has an accumulated deficit of $245.6 million as of September 30, 2025. Net cash used in operating activities was $31.5 million for the nine months ended September 30, 2025, indicating a significant cash burn rate without current revenue streams.

Analyst Insight

Investors should exercise extreme caution and consider the high-risk nature of ACHV's operations. Monitor progress on cytisinicline's regulatory approval closely, as this is the sole product candidate and its success is critical for the company's viability. Be prepared for potential future equity offerings that could dilute existing shareholder value.

Financial Highlights

debt To Equity

N/A

revenue

N/A

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$39.986M

eps

-$0.28

gross Margin

N/A

cash Position

$48.114M

revenue Growth

N/A

Key Numbers

• $39.986M — Net Loss (Increased from $27.467M in 2024 for the nine months ended September 30, 2025)
• $40.149M — Total Operating Expenses (Increased from $26.879M in 2024 for the nine months ended September 30, 2025)
• $19.124M — Research and Development Expenses (Increased from $15.521M in 2024 for the nine months ended September 30, 2025)
• $21.025M — General and Administrative Expenses (Increased from $11.358M in 2024 for the nine months ended September 30, 2025)
• $48.114M — Cash, Cash Equivalents and Marketable Securities (As of September 30, 2025, up from $34.360M at December 31, 2024)
• $45.264M — Net Cash Provided by Financing Activities (For the nine months ended September 30, 2025, primarily from public offerings)
• $245.564M — Accumulated Deficit (As of September 30, 2025, indicating historical losses)
• $31.488M — Net Cash Used in Operating Activities (For the nine months ended September 30, 2025, reflecting cash burn)
• 52,812,488 — Common Stock Shares Outstanding (As of September 30, 2025, increased from 34,685,072 at December 31, 2024 due to offerings)
• $0.28 — Basic and Diluted Net Loss Per Common Share (Q3 2025) (For the three months ended September 30, 2025, compared to $0.36 in Q3 2024)

Key Players & Entities

• Achieve Life Sciences, Inc. (company) — Registrant
• FDA (regulator) — U.S. Food and Drug Administration
• Sopharma (company) — Third-party supplier of cytisinicline
• $39.986 million (dollar_amount) — Net loss for nine months ended September 30, 2025
• $27.467 million (dollar_amount) — Net loss for nine months ended September 30, 2024
• $40.149 million (dollar_amount) — Total operating expenses for nine months ended September 30, 2025
• $26.879 million (dollar_amount) — Total operating expenses for nine months ended September 30, 2024
• $48.114 million (dollar_amount) — Cash, cash equivalents and marketable securities as of September 30, 2025
• $45.264 million (dollar_amount) — Net cash provided by financing activities for nine months ended September 30, 2025
• $245.564 million (dollar_amount) — Accumulated deficit as of September 30, 2025

FAQ

Risk Factors

• Substantial Accumulated Deficit and Need for Future Financing [high — financial]: The company has an accumulated deficit of $245.564 million as of September 30, 2025. This substantial deficit, coupled with ongoing operating losses, indicates a history of unprofitability and a significant reliance on external funding to sustain operations and advance its cytisinicline development program.
• Going Concern Uncertainty [high — financial]: The company's recurring losses and substantial accumulated deficit raise substantial doubt about its ability to continue as a going concern. Achieve Life Sciences relies heavily on future financing activities to fund its operations, including the development of cytisinicline, and any inability to secure such funding could jeopardize its viability.
• Increased Operating Expenses [medium — operational]: Total operating expenses increased by 49.4% to $40.149 million for the nine months ended September 30, 2025, from $26.879 million in the prior year period. This surge was driven by a significant increase in General and Administrative expenses, which more than doubled to $21.025 million from $11.358 million, alongside a rise in R&D expenses.
• Dependence on Cytisinicline Development Success [high — operational]: The company's primary focus is the development of cytisinicline. The success of this drug candidate is critical to the company's future prospects. Any delays, setbacks, or failure in clinical trials or regulatory approval processes for cytisinicline would have a material adverse impact on the company's financial condition and ability to continue operations.
• Drug Development and Regulatory Approval Risks [high — regulatory]: Achieve Life Sciences is subject to extensive regulatory oversight by agencies like the FDA. The development and commercialization of pharmaceutical products involve significant risks, including the possibility of delays in clinical trials, failure to demonstrate safety and efficacy, and challenges in obtaining regulatory approval. These factors can significantly impact timelines and costs.

Industry Context

Achieve Life Sciences operates in the highly competitive biopharmaceutical industry, focusing on developing novel treatments for smoking cessation. The market for smoking cessation aids is significant, but also crowded with various pharmaceutical and behavioral interventions. Success hinges on demonstrating clinical efficacy and safety, navigating complex regulatory pathways, and securing substantial funding for development and commercialization.

Regulatory Implications

As a clinical-stage biopharmaceutical company, ACHV is subject to stringent regulatory scrutiny from bodies like the FDA. The development of cytisinicline requires successful completion of clinical trials and adherence to rigorous manufacturing and marketing standards. Any regulatory delays or failures in demonstrating safety and efficacy could severely impact the company's timeline and financial resources.

What Investors Should Do

1. Monitor cash burn and future financing activities closely.
2. Evaluate the progress and de-risking of the cytisinicline development program.
3. Assess the significant increase in General and Administrative expenses.

Key Dates

• 2025-09-30: Nine months ended September 30, 2025 — Reported a net loss of $39.986 million and total operating expenses of $40.149 million, reflecting increased investment in R&D and G&A.
• 2025-06-01: Public Offering — Generated $41.140 million in gross proceeds, bolstering the company's cash position and providing runway for cytisinicline development.
• 2025-09-30: Cash, Cash Equivalents and Marketable Securities — Stood at $48.114 million, an increase from $34.360 million at December 31, 2024, primarily due to successful financing activities.
• 2025-09-30: Accumulated Deficit — Reached $245.564 million, highlighting the company's historical unprofitability and reliance on external funding.

Glossary

Accumulated Deficit

The total cumulative net losses of a company since its inception, minus any cumulative net income. It represents the total historical losses that have not been offset by profits. (Indicates the company's long-term unprofitability and reliance on external capital to fund operations, as seen with ACHV's $245.564 million deficit.)

Going Concern

An accounting assumption that a business will continue to operate for the foreseeable future. If there is substantial doubt about a company's ability to continue as a going concern, it must be disclosed. (ACHV faces going concern uncertainty due to its operating losses and accumulated deficit, highlighting the risk of its inability to meet future obligations without additional financing.)

Cytisinicline

A prescription medication developed by Achieve Life Sciences intended for smoking cessation. (This is the company's primary drug candidate, and its successful development and approval are critical to ACHV's future revenue and viability.)

Net Cash Used in Operating Activities

The amount of cash a company has spent on its core business operations during a period. A negative number indicates cash is being consumed by operations. (ACHV used $31.488 million in operating activities for the nine months ended September 30, 2025, demonstrating significant cash burn from its ongoing development efforts.)

Year-Over-Year Comparison

For the nine months ended September 30, 2025, Achieve Life Sciences reported a significantly wider net loss of $39.986 million compared to $27.467 million in the same period of 2024, a 45.6% increase. This was driven by a 49.4% surge in total operating expenses to $40.149 million, with General and Administrative expenses more than doubling. Despite the increased cash burn, the company's cash position improved to $48.114 million due to successful equity financing, which also led to an increase in outstanding shares. New risks related to the substantial increase in operating expenses and continued reliance on financing are evident.

Key Financial Figures

• $0.001 — ch registered Common Stock, par value $0.001 per share ACHV The Nasdaq Capital M

Filing Documents

• achv-20250930.htm (10-Q) — 2455KB
• achv-ex31_1.htm (EX-31.1) — 12KB
• achv-ex31_2.htm (EX-31.2) — 12KB
• achv-ex32_1.htm (EX-32.1) — 7KB
• achv-ex32_2.htm (EX-32.2) — 7KB
• 0001193125-25-268074.txt ( ) — 9404KB
• achv-20250930.xsd (EX-101.SCH) — 1448KB
• achv-20250930_htm.xml (XML) — 1521KB

Financial Information

Part I. Financial Information 5 Item 1 Consolidated Financial Statements (unaudited) 5 Consolidated Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024 5 Consolidated Statements of Loss and Comprehensive Loss (unaudited) for the three and nine months ended September 30, 2025 and September 30, 2024 6 Consolidated Statements of Cash Flows (unaudited) for the nine months ended September 30, 2025 and September 30, 2024 7 Consolidated Statements of Stockholders' Equity (unaudited) for the nine months ended September 30, 2025 and September 30, 2024 8

Notes to Consolidated Financial Statements (unaudited)

Notes to Consolidated Financial Statements (unaudited) 9 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 23 Item 4.

Controls and Procedures

Controls and Procedures 31

Other Information

Part II. Other Information 32 Item 1A.

Risk Factors

Risk Factors 32 Item 6. Exhibits 66 Items 2, 3, 4 and 5 are not applicable and therefore have been omitted.

Signatures

Signatures 67 2 INFORMATION REGARDING FORWARD LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a number of risks and uncertainties. We caution readers that any forward-looking statement is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking statement. These statements are based on current expectations of future events. Such statements include, but are not limited to, statements about future financial and operating results, plans, objectives, expectations and intentions, costs and expenses, interest rates, outcome of contingencies, financial condition, results of operations, liquidity, business strategies, cost savings, objectives of management and other statements that are not historical facts. You can find many of these statements by looking for words like "believes," "expects," "anticipates," "estimates," "may," "should," "will," "could," "plan," "intend" or similar expressions in this Quarterly Report on Form 10-Q or in documents incorporated by reference into this Quarterly Report on Form 10-Q. We intend that such forward-looking statements be subject to the safe harbors created thereby. Examples of these forward-looking statements include, but are not limited to: anticipated regulatory filings and U.S. Food and Drug Administration, or FDA, responses, recommendations, requirements or additional future clinical trials; our ability to raise additional capital as needed to fund our planned development and commercialization efforts and service our existing debt; the potential benefits and differentiated profile, FDA approval, commercialization and commercial market for cytisinicline; the performance of, and our ability to obtain sufficient supply of cytisinicline in a timely manner from, third-party suppliers and man

View Full Filing

View this 10-Q filing on SEC EDGAR